23andMe acquired by Regeneron Pharmaceuticals for $256m
19/05/2025 | The Register
Regeneron Pharmaceuticals has announced its agreement to acquire the genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction. The deal is expected to close in the third quarter of this year and aims to let 23andMe continue to offer consumer genome services. Regeneron has committed to comply with 23andMe's privacy policies and all applicable laws concerning the use of customer data. The company has also agreed to outline its intended use of the data to a court-appointed overseer.
What is this page?
You are reading a summary article on the Privacy Newsfeed, a free resource for DPOs and other professionals with privacy or data protection responsibilities helping them stay informed of industry news all in one place. The information here is a brief snippet relating to a single piece of original content or several articles about a common topic or thread. The main contributor is listed in the top left-hand corner, just beneath the article title.
The Privacy Newsfeed monitors over 300 global publications, of which more than 6,250 summary articles have been posted to the online archive dating back to the beginning of 2020. A weekly roundup is available by email every Friday.